Clinical biochemistry最新文献

{"title":"Clinical impact of PTEN rs701848 as a predictive marker for breast cancer","authors":"Basma EL-sayed Fotouh ,&nbsp;Mai Abd El-Meguid ,&nbsp;Ghada Maher Salum ,&nbsp;Ghada Nabil El naggar ,&nbsp;Ahmed F. El-Sayed ,&nbsp;Reham Mohammed Dawood","doi":"10.1016/j.clinbiochem.2025.110872","DOIUrl":"10.1016/j.clinbiochem.2025.110872","url":null,"abstract":"<div><h3>Background</h3><div>The incidence of Breast cancer (BC) is currently augmented and it has become the most common malignant cancer in females. Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene as a result of blocking the phosphorylation of PIP3 in PI3K pathway.</div></div><div><h3>Methods</h3><div>The computational bioinformatics tools were performed to determine the link between PTEN rs701848T/C genetic variants and breast cancer progression. 50 healthy matched controls and 100 Egyptian women with breast cancer were enrolled in the study. The PTEN rs701848T/C polymorphism was assessed using qRT-PCR. Then the proteomic level of PTEN was measured by ELISA technique. Results: Breast cancer patients had considerably higher (TC) genotype frequency than controls, p = 0.03. Moreover, TC carriers had a higher chance of developing tumors with advanced stage, big tumor size, and metastasis at further sites. Regarding proteomic level of PTEN, a remarkable decline was correlated significantly with disease progression. Moreover, the ROC curve analysis showed that the PTEN protein showed comparable diagnostic accuracy in distinguishing between different BC stages.</div></div><div><h3>Conclusion</h3><div>The current research provides insight into the impact of PTEN as a predictive marker for BC development and progression at genomic and proteomic levels.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"136 ","pages":"Article 110872"},"PeriodicalIF":2.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142964142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CXCL5 as a biomarker for early diagnosis and prognosis of sepsis: A comprehensive clinical evaluation","authors":"Rui Zhao ,&nbsp;HangBo Li ,&nbsp;Banglao Xu ,&nbsp;Ju Cao","doi":"10.1016/j.clinbiochem.2025.110878","DOIUrl":"10.1016/j.clinbiochem.2025.110878","url":null,"abstract":"<div><h3>Objectives</h3><div>Sepsis, a critical condition caused by a dysregulated host response to infection, has high morbidity and mortality rates. Timely diagnosis and treatment are vital for improving patient outcomes. This study explores the potential role of CXCL5 in the diagnosis, severity assessment, and prognosis of sepsis.</div></div><div><h3>Design and methods</h3><div>We included 147 sepsis patients, 50 patients with systemic inflammatory response syndrome (SIRS) and 120 healthy controls. Serum CXCL5 levels, inflammation scores (APACHE II, SOFA), and other laboratory indicators were recorded. Univariate and multivariate logistic regression analyses were conducted to assess the relationship between CXCL5 and sepsis diagnosis, severity, and prognosis. A prognostic nomogram was constructed and evaluated using receiver operator characteristic curves, calibration curves, and clinical decision curves.</div></div><div><h3>Results</h3><div>Serum CXCL5 levels in sepsis patients were significantly higher than those in patients with SIRS and healthy controls. CXCL5 was identified as a risk factor for sepsis diagnosis. CXCL5 levels were significantly elevated in patients with septic shock (P = 0.04) and in deceased patients compared to survivors (P &lt; 0.001). The prognostic model, incorporating CXCL5, lactate, APACHE II scores, C-reactive protein levels, and respiratory rate, demonstrated high predictive accuracy with an area under the curve of 0.873. Calibration and decision curve analyses demonstrated the model’s good predictive performance and potential clinical value.</div></div><div><h3>Conclusions</h3><div>Serum CXCL5 concentration is a promising biomarker for enhancing the diagnostic accuracy and prognostic evaluation of sepsis. The constructed multivariate prediction model offers new insights into sepsis prognosis, but its direct application in clinical practice requires further validation.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"136 ","pages":"Article 110878"},"PeriodicalIF":2.5,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of phospholipid transfer protein (PLTP) and the effect of genetic variant rs5072 on hypertriglyceridemia and atherogenic dyslipidemia in children and adolescents from Southeastern Mexico","authors":"Luis E. Jiménez-Martínez ,&nbsp;Anne Santerre ,&nbsp;Héctor Ochoa-Díaz-López ,&nbsp;Zendy Evelyn Olivo-Vidal ,&nbsp;Itandehui Castro-Quezada ,&nbsp;Cesar Antonio Irecta-Nájera","doi":"10.1016/j.clinbiochem.2024.110871","DOIUrl":"10.1016/j.clinbiochem.2024.110871","url":null,"abstract":"<div><h3>Introduction</h3><div>Dyslipidemia is characterized by changes in lipid and lipoprotein levels in the blood where phospholipid transfer protein (PLTP) helps to regulate and modulate the size of high-density lipoproteins (HDL), working on the reverse transport of cholesterol. ApoA-1 is the primary protein component of HDL, and certain genetic variants like rs5072, have been associated with hypertriglyceridemia in children. This study aimed to explore the association between PLTP concentrations and the effect of the genetic variant <em>APOA1</em> rs5072 on hypertriglyceridemia and atherogenic dyslipidemia (AD) in the pediatric population of Southeastern Mexico.</div></div><div><h3>Materials and methods</h3><div>A cross-sectional study was carried out with a case-control design for 364 pediatric patients between 2 and 17 years old in Chiapas and Tabasco, Mexico. Serum samples were used to evaluate PLTP concentrations using ELISA kits, and DNA from peripheral blood samples was used to study genetic variation using q-PCR with TaqMan® probes. For statistical analysis, Student <em>t</em>-test for media comparison, Chi-square for frequency and Pearson analysis for correlation was performed. The software SNPStats was used for inheritance models.</div></div><div><h3>Results</h3><div>Children with hypertriglyceridemia had higher levels of PLTP (8.3 ± 6.5 ng/ml) than the control group (6.4 ± 4.5 ng/ml). Similarly, the pediatric patients with AD had higher PLTP levels of 8.0 ± 6 ng/ml, mainly in children with high triglycerides who were between 10 and 17 years old (9.7 ± 8.0 ng/ml). Also, it was found that the genetic variant rs5072 had a protective effect against hypertriglyceridemia (OR = 0.61, <em>p = 0.024</em>) in the over-dominant inheritance model.</div></div><div><h3>Conclusion</h3><div>PLTP levels increase in pediatric patients aged 10 to 17 years with a diagnosis of hypertriglyceridemia and AD. The genetic variant rs5072 has a protective effect in hypertriglyceridemia.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"136 ","pages":"Article 110871"},"PeriodicalIF":2.5,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of glucose and lactate in cerebrospinal fluid (CSF) on a Radiometer blood gas analyzer ABL90 Flex plus","authors":"Vinita Thakur ,&nbsp;Olatunji Anthony Akerele ,&nbsp;Edward Randell","doi":"10.1016/j.clinbiochem.2025.110876","DOIUrl":"10.1016/j.clinbiochem.2025.110876","url":null,"abstract":"<div><h3>Purpose</h3><div>Rapid determination of cerebrospinal fluid</div><div>(CSF) glucose and lactate is required by emergency rooms and intensive care units. Long turnaround time (TAT) on test results negatively impacts timely diagnosis and treatment of neurological infections like meningitis.</div></div><div><h3>Methods</h3><div>The CSF glucose and lactate assays were evaluated on a blood gas analyzer, Radiometer ABL90 Flex Plus. Linearity, limit of quantitation (LOQ), and precision were determined using fresh and spiked patient CSF samples. Fifty-four fresh and 49 frozen CSF samples were used to compare the method against<!--> <!-->Abbott<!--> <!-->Architect<!--> <!-->C16000. An inter-laboratory comparison was done across eight hospital sites having ABL90 Flex Plus. The stability of both tests was tested for 48 h at ambient and refrigerated temperatures. Results were compared between centrifuged and uncentrifuged fresh CSF samples to determine if particulate in uncentrifuged samples impacted analysis.</div></div><div><h3>Results</h3><div>Glucose and lactate assays were linear over a broad analytical range of 1–45 mmol/L and 0–37 mmol/L, respectively, and demonstrated a good correlation with the routine chemistry laboratory method. LOQ was determined as 0.4 mmol/L for CSF glucose with a coefficient of variation (CV) of 14.7 % and 0.2 mmol/L with 0 % CV for CSF lactate respectively. Repeatability and reproducibility show small imprecision for both these assays. Glucose and lactate were stable for over 48 h at room or refrigeration temperatures. Sample particulates had no impact on the measurement. The inter-laboratory comparison was within total allowable error for glucose and lactate.</div></div><div><h3>Conclusions</h3><div>Acceptable performance characteristics, small sample volume, and rapid TAT make ABL90 Flex Plus an acceptable alternative analyzer for CSF glucose and lactate.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"136 ","pages":"Article 110876"},"PeriodicalIF":2.5,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amikacin therapeutic drug monitoring: Evaluation of therapy performance and analytical techniques in a developing country setting","authors":"Nadine Arnold Steffens ,&nbsp;Rodrigo Redel Petreceli ,&nbsp;Victor Coden Azevedo ,&nbsp;Adriana Streher França ,&nbsp;Roberta Zilles Hahn ,&nbsp;Amanda Pacheco Bondan ,&nbsp;Rafael Linden ,&nbsp;Mariele Feiffer Charão ,&nbsp;Alexandre de Vargas Schwarzbold ,&nbsp;Natália Brucker","doi":"10.1016/j.clinbiochem.2025.110874","DOIUrl":"10.1016/j.clinbiochem.2025.110874","url":null,"abstract":"<div><h3>Introduction</h3><div>Healthcare systems face several challenges, with microbial infections being one of the main concerns. Therapeutic drug monitoring (TDM) is a strategy that has been encouraged to optimize antimicrobial regimens, particularly those with significant toxicity and narrow therapeutic indices, such as amikacin (AMK). We aimed to evaluate AMK concentrations of patients in a non-routine TDM setting and compare the performance of immunoassay and chromatography methods for routine clinical use.</div></div><div><h3>Material and Methods</h3><div>In this prospective study, peak (C_max) and trough (C_min) plasma samples were collected from 39 adult patients and quantified by ultra-performance liquid chromatography coupled with mass spectrometry (UPLC-MS/MS). Relevant clinical information was collected from medical records. AMK concentrations and clinical data were analyzed to evaluate therapy performance and influencing factors. In addition, fluorescence polarized immunoassay (FPIA) and UPLC-MS/MS were compared with Passing-Bablok regression and Bland-Altman plot analysis.</div></div><div><h3>Results</h3><div>AMK concentrations varied widely, with a median C_max of 41.40 µg/mL (interquartile range [IQR] 27.60 – 56.75 µg/mL) and a median C_min of 1.87 µg/mL (IQR 0.7 – 6.19 µg/mL). A high proportion of patients (83.1 %) failed to achieve the C_max therapeutic target, while 31.7 % failed to achieve the C_min therapeutic target. Overall, elderly patients and those with reduced renal function had higher C_max target attainment, while the same groups had lower C_min target attainment. The method comparison showed a mean difference of 1.54 % (limits of agreement −42.46 % to 45.54 %) in measured concentrations, with good correlation and no constant or proportional differences.</div></div><div><h3>Conclusion</h3><div>Many patients failed to reach the C_max target and were at risk of treatment failure, although adequate C_min was achieved more often. TDM with dose adjustments could improve AMK therapy, but further research is needed.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"136 ","pages":"Article 110874"},"PeriodicalIF":2.5,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Important quality parameters for macrocomplex investigation for cardiac troponin","authors":"Peter A. Kavsak ,&nbsp;Won-Shik Choi ,&nbsp;Paul Malinowski ,&nbsp;Wael L. Demian ,&nbsp;Vikas Tandon ,&nbsp;Craig Ainsworth","doi":"10.1016/j.clinbiochem.2024.110866","DOIUrl":"10.1016/j.clinbiochem.2024.110866","url":null,"abstract":"","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"135 ","pages":"Article 110866"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142852951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced detection and Characterization of M-proteins in multiple myeloma patients using An Agilent AssayMAP Bravo liquid handling system coupled to an LC-QTOF","authors":"Matthew Nichols ,&nbsp;Chai W. Phua ,&nbsp;Martha L. Louzada ,&nbsp;Benjamin D. Hedley ,&nbsp;Vipin Bhayana ,&nbsp;Ian Chin-Yee ,&nbsp;Angela C. Rutledge","doi":"10.1016/j.clinbiochem.2024.110870","DOIUrl":"10.1016/j.clinbiochem.2024.110870","url":null,"abstract":"<div><h3>Background</h3><div>Mass spectrometry methods are emerging as tools to detect M−proteins in the serum of multiple myeloma patients with increased sensitivity and specificity compared to traditional electrophoretic methods.</div></div><div><h3>Methods</h3><div>A liquid handling system, the Agilent AssayMAP Bravo, with liquid chromatography high-resolution quadrupole-time-of-flight (LC-QTOF) mass spectrometry to analyze intact light chains was compared to immunofixation electrophoresis (IFE) for M−protein analysis. 210 patient serum samples were analyzed in a split sample comparison (LC-QTOF vs. IFE). LC-QTOF and IFE were interpreted by different individuals in a blinded fashion and results were grouped into four categories: IFE+/QTOF+, IFE+/QTOF-, IFE-/QTOF+, or IFE-/QTOF-.</div></div><div><h3>Results</h3><div>The LC-QTOF method is able to determine the isotype of M−proteins in a similar fashion to IFE. The estimated limit of detection was ∼ 35 mg/L for adalimumab. For split patient samples, 168 were QTOF+/IFE+, 25 were QTOF-/IFE-, 14 were QTOF+/IFE-, and three were QTOF-/IFE + . Excluding the QTOF+/IFE- results due to the improved sensitivity of the LC-QTOF method, the concordance of LC-QTOF with IFE was ∼ 98 %. The LC-QTOF method also offers improved specificity compared to electrophoretic methods due to inclusion of the accurate mass of the light chains.</div></div><div><h3>Conclusions</h3><div>The LC-QTOF method was deemed fit for clinical use as a qualitative test with increased sensitivity and specificity compared to IFE. The LC-QTOF can also better resolve therapeutic and multiple myeloma IgG-kappa M−proteins, which present a challenge for electrophoretic methods. Future work will determine suitability of this method as an assessment of minimal residual disease status.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"135 ","pages":"Article 110870"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"YKL-40 levels in cerebrospinal fluid serve as a diagnostic biomarker for post-neurosurgical bacterial meningitis in patients with stroke","authors":"Jingtao Wang,&nbsp;Xiaofeng Wang,&nbsp;Hongwei Cheng,&nbsp;Lei Ye","doi":"10.1016/j.clinbiochem.2024.110864","DOIUrl":"10.1016/j.clinbiochem.2024.110864","url":null,"abstract":"<div><h3>Introduction</h3><div>Previous studies have reported that YKL-40 can serve as a biomarker of infectious diseases and different stroke types. However, evidence supporting its role in diagnosing post-neurosurgical bacterial meningitis (PNBM) remains lacking.</div></div><div><h3>Methods</h3><div>A total of 110 patients with stroke who underwent neurosurgical treatment were recruited. Among these, 36 were diagnosed with PNBM based on the results of bacterial culture/Gram staining or cerebrospinal fluid (CSF) characteristics. CSF levels of YKL-40 and other biomarkers with potential diagnostic utility for PNBM were statistically analysed using univariate and logistic regression models. Receiver operating characteristic (ROC) analysis was performed to investigate diagnostic efficiency.</div></div><div><h3>Results</h3><div>According to univariate analysis, CSF levels of glucose, total protein, white blood cells, polymorphocytes, and YKL-40, as well as the CSF-to-blood glucose ratio, were significantly different between the PNBM and non-PNBM groups. Logistic regression analysis revealed that glucose (p = 0.026), total protein (p = 0.028), and YKL-40 (p = 0.006) levels in the CSF may have independent diagnostic utility for PNBM. Among the three biomarkers, CSF-to-blood glucose (area under the receiver operating characteristic curve [AUC] 0.9208) and YKL-40 (AUC 0.9587) demonstrated strong diagnostic utility.</div></div><div><h3>Conclusion</h3><div>CSF levels of YKL-40, glucose, and total protein played independent roles in the diagnosis of PNBM in patients with stroke.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"135 ","pages":"Article 110864"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory study of extracellular matrix biomarkers for non-invasive liver fibrosis staging: A machine learning approach with XGBoost and explainable AI","authors":"Valeria Carnazzo ,&nbsp;Stefano Pignalosa ,&nbsp;Marzia Tagliaferro ,&nbsp;Laura Gragnani ,&nbsp;Anna Linda Zignego ,&nbsp;Cosimo Racco ,&nbsp;Luigi Di Biase ,&nbsp;Valerio Basile ,&nbsp;Gian Ludovico Rapaccini ,&nbsp;Riccardo Di Santo ,&nbsp;Benedetta Niccolini ,&nbsp;Mariapaola Marino ,&nbsp;Marco De Spirito ,&nbsp;Guido Gigante ,&nbsp;Gabriele Ciasca ,&nbsp;Umberto Basile","doi":"10.1016/j.clinbiochem.2024.110861","DOIUrl":"10.1016/j.clinbiochem.2024.110861","url":null,"abstract":"<div><h3>Background</h3><div>Novel circulating markers for the non-invasive staging of chronic liver disease (CLD) are in high demand. Although underutilized, extracellular matrix (ECM) components offer significant diagnostic potential. This study evaluates ECM-related markers in hepatitis C virus (HCV)-positive patients across varying fibrosis stages.</div></div><div><h3>Methods</h3><div>Sixty-eight patients with mild-to-moderate fibrosis (F1-F2), sixty-six with advanced fibrosis (F3-F4), and thirty healthy donors were recruited. Inclusion criteria were detectable HCV-RNA and no other liver diseases or co-infections. Levels of ECM markers—hyaluronic acid (HA), laminin (LN), collagen-III N-peptide (PIIIP N-P), collagen-IV (C-IV)—along with cholylglycine (CG) and Golgi protein-73 (GP73), were measured in serum using the MAGLUMI 800 CLIA platform.</div></div><div><h3>Results</h3><div>Levels of LN, HA, C-IV, PIIIP N-P (p &lt; 0.001), and GP73 (p &lt; 0.01) increased from controls to F1-F2 and F3-F4. CG levels were higher in pathological subjects compared to controls (p &lt; 0.001), but no significant differences emerged between fibrosis stages. These trends persisted after adjusting for age and sex. A multivariate ordinal regression identified LN, PIIIP N-P, and C-IV as promising markers, with an accuracy of 0.77. An XGBoost model improved accuracy to 0.87 and enhanced other metrics. SHAP analysis confirmed these variables as key contributors to the model’s predictions.</div></div><div><h3>Conclusion</h3><div>This study underscores the potential of ECM biomarkers, particularly LN, PIIIP N-P, and C-IV, in non-invasively staging CLD. Furthermore, our preliminary data suggest that a machine learning approach, combined with explainable AI, could further enhance diagnostic accuracy, potentially reducing the need for invasive biopsies.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"135 ","pages":"Article 110861"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing the SARS-CoV-2 antibody response and associations with patient factors: Serological profiling of participants enrolled in the GENCOV study","authors":"Gregory Morgan ,&nbsp;Chun Yiu Jordan Fung ,&nbsp;Anne-Claude Gingras ,&nbsp;Karen Colwill ,&nbsp;Laurent Briollais ,&nbsp;Erika Frangione ,&nbsp;Dawit Wolday ,&nbsp;Freda Qi ,&nbsp;Adrian Pasculescu ,&nbsp;Melanie Delgado-Brand ,&nbsp;Genevieve Mailhot ,&nbsp;Tulunay Tursun ,&nbsp;Saranya Arnoldo ,&nbsp;Erin Bearss ,&nbsp;Alexandra Binnie ,&nbsp;Bjug Borgundvaag ,&nbsp;Selina Casalino ,&nbsp;Sunakshi Chowdhary ,&nbsp;Marc Dagher ,&nbsp;Luke Devine ,&nbsp;Jennifer Taher","doi":"10.1016/j.clinbiochem.2024.110859","DOIUrl":"10.1016/j.clinbiochem.2024.110859","url":null,"abstract":"<div><h3>Introduction</h3><div>The GENCOV study sought to evaluate serological differences between individuals with differing COVID-19 severity and outcomes. We assessed the SARS-CoV-2 antibody response of GENCOV participants cross-sectionally 1-, 6-, and 12-months following COVID-19 diagnosis to identify patient factors associated with more robust and durable humoral immune responses.</div></div><div><h3>Materials and Methods</h3><div>COVID-19 patients and a control cohort of vaccinated infection-naïve participants were recruited at hospital sites across the Greater Toronto Area in Ontario, Canada. Commercially available and laboratory-developed serological assays were used to characterize features of participants’ antibody responses, including both binding and neutralizing antibodies. Regression analyses were performed to identify associations between participant characteristics and features of the SARS-CoV-2 antibody response.</div></div><div><h3>Results</h3><div>Samples were obtained from participants 1- (n = 938), 6- (n = 842), and 12-months (n = 662) post-infection or vaccination. At all time points, vaccinees, and to a greater extent those who were both infected and vaccinated, had significantly elevated anti-spike antibody levels compared to unvaccinated participants. Increasing age and/or illness severity were associated with significantly higher antibody levels among unvaccinated participants. Among vaccines, those who were vaccinated after infection (i.e., hybrid immunity) had consistently higher antibody levels compared to participants who were infection-naïve or vaccinated before their infection (i.e., breakthrough infections). Additionally, receiving more vaccine doses and having a more recent vaccination were strongly associated with higher antibody levels across all time points.</div></div><div><h3>Conclusions</h3><div>Our findings highlight various patient factors, including vaccination, which contribute to robust, durable SARS-CoV-2 antibody responses. Overall, the findings presented here may inform future vaccine development and rollout plans.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"135 ","pages":"Article 110859"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}